Literature DB >> 22635208

Obstetric and vascular APS: same autoantibodies but different diseases?

P L Meroni1, E Raschi, C Grossi, F Pregnolato, L Trespidi, B Acaia, M O Borghi.   

Abstract

Beta2 glycoprotein I (β2GPI)-dependent antiphospholipid antibodies (aPLs) are the main pathogenic autoantibody population and at the same time the laboratory diagnostic tool for the antiphospholipid syndrome (APS). These antibodies are responsible for both the vascular and the obstetric manifestations of the syndrome but the pathogenic mechanisms behind these manifestations are not the same. For example, thrombotic events do not appear to play a major role in APS miscarriages and a direct reactivity of β2GPI-dependent aPLs on decidual and trophoblast cells was reported. A local expression of β2GPI on these tissues was reported both in physiological conditions and in APS women, thus explaining the local tropism of the autoantibodies. The two hit hypothesis was suggested to explain why the vascular manifestations of APS may occur only occasionally in spite of the persistent presence of aPLs. This is not apparently the case for the obstetric variant of the syndrome, making the difference even more striking. A different pathogenesis may also provide the rationale for the well-known fact that the vascular and the obstetric manifestations may occur independently although in a minority of cases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22635208     DOI: 10.1177/0961203312438116

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  17 in total

1.  Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy.

Authors:  Karoline Mayer-Pickel; Katharina Eberhard; Uwe Lang; Mila Cervar-Zivkovic
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

2.  Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.

Authors:  Eva N Hamulyák; Luuk Jj Scheres; Mauritia C Marijnen; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2020-05-02

Review 3.  Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals.

Authors:  Mirjana Bećarević
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

4.  Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies.

Authors:  Zola Chihombori Quao; Mancy Tong; Elena Bryce; Seth Guller; Lawrence W Chamley; Vikki M Abrahams
Journal:  Am J Reprod Immunol       Date:  2017-11-14       Impact factor: 3.886

Review 5.  Management of recurrent thrombosis in antiphospholipid syndrome.

Authors:  Cecilia Nalli; Laura Andreoli; Cinzia Casu; Angela Tincani
Journal:  Curr Rheumatol Rep       Date:  2014-03       Impact factor: 4.592

Review 6.  TNF-alpha and annexin A2: inflammation in thrombotic primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević
Journal:  Rheumatol Int       Date:  2016-10-04       Impact factor: 2.631

7.  Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Authors:  John V Ilekis; Ekaterini Tsilou; Susan Fisher; Vikki M Abrahams; Michael J Soares; James C Cross; Stacy Zamudio; Nicholas P Illsley; Leslie Myatt; Christine Colvis; Maged M Costantine; David M Haas; Yoel Sadovsky; Carl Weiner; Erik Rytting; Gene Bidwell
Journal:  Am J Obstet Gynecol       Date:  2016-03-10       Impact factor: 8.661

Review 8.  Anticoagulation in management of antiphospholipid antibody syndrome in pregnancy.

Authors:  Michael D Lockshin
Journal:  Clin Lab Med       Date:  2013-04-19       Impact factor: 1.935

9.  Antiphospholipid antibody-induced miR-146a-3p drives trophoblast interleukin-8 secretion through activation of Toll-like receptor 8.

Authors:  Stefan M Gysler; Melissa J Mulla; Marta Guerra; Jan J Brosens; Jane E Salmon; Lawrence W Chamley; Vikki M Abrahams
Journal:  Mol Hum Reprod       Date:  2016-03-29       Impact factor: 4.025

10.  Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study.

Authors:  Anna Broder; Wenzhu B Mowrey; Mimi Kim; Irina Murakhovskaya; Henny Billett; Joel Neugarten; Karen H Costenbader; Chaim Putterman
Journal:  Rheumatology (Oxford)       Date:  2015-12-24       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.